Literature DB >> 19968494

In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.

G Metro1, Z Zheng, A Fabi, M Schell, B Antoniani, M Mottolese, A N Monteiro, P Vici, S Lara Rivera, D Boulware, F Cognetti, G Bepler.   

Abstract

Ribonucleotide reductase 1 (RRM1) is a determinant of gemcitabine efficacy in non-small-cell lung cancer and pancreatic cancer. We investigated the protein levels of RRM1 and two other DNA repair enzymes, ERCC1 and BRCA1, in 55 metastatic breast cancer (MBC) patients undergoing gemcitabine-based chemotherapy. With automated in situ protein quantification (AQUA v1.6), the average scores for RRM1, ERCC1, and BRCA1 ranged from 245.6-2774.1, 74.0-410.3, and 54.4-1833.1, respectively. They were significantly associated with each other (Spearman's rho > or = .36; p < or = .007). Given their pattern of distribution, RRM1 and BRCA1 are potentially suitable markers for clinical decision making in MBC.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19968494      PMCID： PMC3565222          DOI： 10.3109/07357900903095722

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  32 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer.

Authors:  P O Chappuis; J Goffin; N Wong; C Perret; P Ghadirian; P N Tonin; W D Foulkes
Journal:  J Med Genet       Date:  2002-08       Impact factor: 6.318

3.  An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.

Authors:  Jennifer D Davidson; Liandong Ma; Michael Flagella; Sandaruwan Geeganage; Lawrence M Gelbert; Christopher A Slapak
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

4.  Automated subcellular localization and quantification of protein expression in tissue microarrays.

Authors:  Robert L Camp; Gina G Chung; David L Rimm
Journal:  Nat Med       Date:  2002-10-21       Impact factor: 53.440

5.  Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.

Authors:  Rafael Rosell; Kathleen D Danenberg; Vincente Alberola; Gerold Bepler; Jose Javier Sanchez; Carlos Camps; Mariano Provencio; Dolores Isla; Miquel Taron; Pilar Diz; Angel Artal
Journal:  Clin Cancer Res       Date:  2004-02-15       Impact factor: 12.531

6.  BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.

Authors:  Miquel Taron; Rafael Rosell; Enriqueta Felip; Pedro Mendez; John Souglakos; Maria Sanchez Ronco; Cristina Queralt; Joaquim Majo; Jose Miguel Sanchez; Jose Javier Sanchez; Jose Maestre
Journal:  Hum Mol Genet       Date:  2004-08-18       Impact factor: 6.150

7.  RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer.

Authors:  Gerold Bepler; Swati Sharma; Alan Cantor; Ashish Gautam; Eric Haura; George Simon; Anupama Sharma; Eric Sommers; Lary Robinson
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544

8.  Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.

Authors:  John R Goffin; Pierre O Chappuis; Louis R Bégin; Nora Wong; Jean-Sébastien Brunet; Nancy Hamel; Ann-Josée Paradis; Jeff Boyd; William D Foulkes
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

9.  Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.

Authors:  T Byrski; T Huzarski; R Dent; J Gronwald; D Zuziak; C Cybulski; J Kladny; B Gorski; J Lubinski; S A Narod
Journal:  Breast Cancer Res Treat       Date:  2008-07-23       Impact factor: 4.872

10.  BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.

Authors:  Jennifer E Quinn; Richard D Kennedy; Paul B Mullan; Paula M Gilmore; Michael Carty; Patrick G Johnston; D Paul Harkin
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701
View more
  12 in total

Review 1.  Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures.

Authors:  Simona Carnio; Silvia Novello; Mauro Papotti; Marco Loiacono; Giorgio Vittorio Scagliotti
Journal:  Transl Lung Cancer Res       Date:  2013-10

2.  Association of novel gene polymorphisms RRM1 -756T>C and -269 C>A with breast cancer.

Authors:  Dar-Ren Chen; Chun-Yi Chuang; Buor-Chang Wu; Shun-Fa Yang; Yu-Hsien Peng; Hsiu-Ting Tsai
Journal:  J Clin Lab Anal       Date:  2014-02-27       Impact factor: 2.352

3.  High excision repair cross-complementation group 1 expression is associated with favorable prognostic factors in breast cancer.

Authors:  Dong Hyun Kim; Hyunjoo Lee; Dong-Hoon Kim; Seoung Wan Chae; Jin Hee Sohn; Kyungeun Kim; Sung-Im Do
Journal:  Oncol Lett       Date:  2017-08-09       Impact factor: 2.967

4.  ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis.

Authors:  Gerold Bepler; Ken André Olaussen; Anne-Lise Vataire; Jean-Charles Soria; Zhong Zheng; Ariane Dunant; Jean-Pierre Pignon; Michael J Schell; Pierre Fouret; Robert Pirker; Martin Filipits; Elisabeth Brambilla
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

5.  KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer.

Authors:  Vienna Ludovini; Biagio Ricciuti; Francesca R Tofanetti; Clelia Mencaroni; Diana Giannarelli; Angelo Sidoni; Maria S Reda; Annamaria Siggillino; Sara Baglivo; Lucio Crinò; Guido Bellezza; Rita Chiari; Giulio Metro
Journal:  Mol Clin Oncol       Date:  2018-10-01

6.  The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes.

Authors:  Dokyung Kim; Woohee Jung; Ja Seung Koo
Journal:  J Korean Med Sci       Date:  2011-02-25       Impact factor: 2.153

7.  Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models.

Authors:  Fabio Parisi; Ana M Gonzalez; Yasmine Nadler; Robert L Camp; David L Rimm; Harriet M Kluger; Yuval Kluger
Journal:  Breast Cancer Res       Date:  2010-09-01       Impact factor: 6.466

8.  Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?

Authors:  Matias E Valsecchi; Thomas Holdbrook; Benjamin E Leiby; Edward Pequignot; Susan J Littman; Charles J Yeo; Jonathan R Brody; Agnieszka K Witkiewicz
Journal:  BMC Cancer       Date:  2012-03-22       Impact factor: 4.430

9.  ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy

Authors:  Mohamed Ali EL Baiomy; Wagdi F El Kashef
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01

10.  Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.

Authors:  Charlotte L T Jørgensen; Bent Ejlertsen; Karsten D Bjerre; Eva Balslev; Dorte L Nielsen; Kirsten V Nielsen
Journal:  BMC Cancer       Date:  2013-11-12       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.